Izokibep

DB19081InvestigationalProtein Based Therapies

Izokibep is under investigation in clinical trial NCT05623345 (Psoriatic Arthritis Study of Izokibep).

Mechanism
Curator reviewed
Also known as
Affibody aby-035 (recombinant human interleukin 17a-binding) · FUSION PROTEIN COMPOSED OF 3 BINDING DOMAINS CONSISTING OF THREE-ALPHA-HELIX MOTIFS, EACH DERIVED FROM THE IMMUNOGLOBULIN (IG)-BINDING Z-DOMAIN OF STAPHYLOCOCCAL PROTEIN A (SPA), ENGINEERED FOR BINDING TO TWO HOMODIMER SUBUNITS OF HUMAN INTERLEUKIN 17A (
Code names
ABY-035 · ABY-035/AFO2 · IMG-020

Resolves to

Compound
UNII8B8VV1W6FZCAS2226130-02-3
Targets
Q16552IL17A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Izokibep, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In